chronic thromboembolic pulmonary hypertension

(redirected from Cteph)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to Cteph: Chronic thromboembolic pulmonary hypertension

chronic thromboembolic pulmonary hypertension

persistent pulmonary hypertension caused by obstruction of a major pulmonary artery by an unresolved embolus or multiple small pulmonary emboli.

chronic thromboembolic pulmonary hypertension

Abbreviation: CTEPH
Pulmonary HTN that results from the migration of blood clots (usually from the lower extremities) into the lungs. Elevated BP in the lungs gradually overloads the right ventricle and causes right-sided heart failure.

Symptoms

Symptoms usually include shortness of breath, esp. during exercise.

Treatment

The disease, when identified, may be treated with surgical removal of blood clots.

See also: hypertension
References in periodicals archive ?
1] More than half (55 percent) of cardiologists and pulmonologists surveyed wish that general practitioners would better understand the specific signs and symptoms of CTEPH and pulmonary arterial hypertension (PAH), so that they can see patients sooner.
We are very pleased to see Bayer's commitment to CTEPH patients and their work to raise awareness about the disease," said Rino Aldrighetti, president and CEO of the Pulmonary Hypertension Association, Silver Spring, Md.
Bayer and PHA celebrate PH Awareness month in November, and will observe CTEPH Awareness Day on November 18 annually moving forward.
Every patient diagnosed with CTEPH should be evaluated by an expert CTEPH team, including a CTEPH physician and PEA surgeons, to assess their candidacy for PEA surgery.
PAH and CTEPH are two rare and life-threatening forms of pulmonary hypertension characterized by significantly increased pressure in the pulmonary arteries.
It is the first and only FDA-approved drug therapy for persistent/recurrent CTEPH after surgical treatment or inoperable CTEPH.
In the first interim analysis in CHEST-2, riociguat was shown to be well tolerated with a good long-term safety profile in patients with CTEPH.
Riociguat is the first drug to demonstrate clinical efficacy in a placebo controlled phase III trial in inoperable CTEPH patients.
If approved by the FDA, riociguat will be the first treatment for inoperable CTEPH or persistent/recurrent CTEPH after surgery and a new treatment for PAH
Riociguat (BAY 63-2521), discovered and developed at the Bayer research laboratories, is an investigational oral soluble guanylate cyclase (sGC) stimulator that is being studied in CTEPH and PAH, as well as other forms of pulmonary hypertension.
Food and Drug Administration (FDA) seeking approval for riociguat, an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH.